Ibrutinib's Asian Standard Therapy Strategy Revealed

Professor Seok-gu Cho and Young-woo Jeon at Yeouido St. Mary's Hospital publish international journals

Disease-free survival of 35 months, best for allogeneic hematopoietic stem cell transplantation on failure

A domestic study shows that allogeneic hematopoietic stem cell transplantation is the ultimate treatment strategy for patients who do not have treatment effect after 3 months after taking Imbruvica (Ibrutinib/Janssen), a kind of hematologic cancer.

 

The researchers also found that the initial prognostic factors of mantle cell lymphoma and the failure to treat early Ibrutinib were a poor risk factor for refractory and recurrent mantle lymphoma.

 

The Korean researchers have suggested a standardized treatment strategy for applying target anticancer drugs in mantle cell lymphoma disease.

 

On the 8th, the research team of Professor Seok-gu Cho and Young-woo Jeon of the Lymphoma Center, Yeouido St.

 

Mary's Hospital, Catholic University, Korea, released the findings.

 

The new drug Ibrutinib is an oral capsule and is a special anticancer drug that kills only cancer cells.

 

It is effective in some patients with lymphoma and attracts attention as a new treatment.

 

Therapeutic research has been difficult for 'relapsed and non-refractory mantle cell lymphoma', which accounts for 6% of non-Hodgkin's lymphoma patients.

 

In particular, the price of new drugs, such as Imbrica, was so expensive that accessibility to patients was low.

 

This is why it is meaningful that a team of professors Seok-gu Cho and Young-woo Jeon at the Yeouido St.

 

Mary's Hospital Lymphoma Center of Catholic University apply a single treatment at a single institution and analyze the Ibrutinib treatment response in the same patient.

 

For four years (2013-2018), the researchers collected patient groups from the Lymphoma-myeloma center of the Seoul St.

 

Mary's Hospital, and the Lymphoma Center of the Yeouido St.

 

Mary's Hospital.

 

Thirty-three patients who were prescribed Ibrutinib for recurrence of disease during the use of R-CHOP, a representative primary treatment, after the diagnosis of mantle cell lymphoma.

 

The team analyzed the effects of Ibrutinib treatment and predictive outcomes.

 

The disease-free survival of patients with refractory and recurrent mantle lymphoma with Ibrutinib was about 35 months, longer than the control group, 12 months.

 

Based on the response for 3 months after taking Ibrutinib, the disease-free survival rate was also classified into ▲ early treatment response group and early treatment failure group.

 

The disease-free survival rate was 82% in the early treatment responders with complete or partial remission and 18% in the early failure groups.

 

The early treatment response group was found to maintain long-term survival while maintaining remission, but the early treatment failure group died within six months.

 

The team found a risk factor that predicted a poor prognosis for patients with refractory and recurrent mantle cell lymphoma.

 

▲The initial prognostic factors of mantle cell lymphoma at first visit were poor, or ▲The initial treatment failed after taking Ibrutinib.

 

It was also confirmed that allogeneic hematopoietic stem cell transplantation was the ultimate treatment for patients who had no therapeutic effect on Iburitinib.

 

Professor Seok-gu Cho (corresponding author) said, "Cortic cell lymphoma is a disease with a very low incidence and a poor recurrence, and the new drug-targeted anticancer drug study is meaningful to patients who relapse during treatment with established and consistent treatments".

 

Professor Cho added, "It also means that the analysis of prognostic factors and prognostic factors for the new drug-targeted anticancer drug is the initial analysis data published for Asians".

 

Professor Jeon Young-woo, the first author, said, “New drug Ibrutinib is not a perfect treatment.

 

Rapidity is most important in treating lymphoma when deciding and switching treatment, and the prognosis is extremely poor.

 

A strategy to improve survival by allogeneic hematopoietic stem cell transplantation is important, and the study was published in the September 2019 issue of Cancer Medicin (IF = 3.35)”.